JP2019509988A - １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用 - Google Patents

１型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用 Download PDF

Info

Publication number
JP2019509988A
JP2019509988A JP2018540786A JP2018540786A JP2019509988A JP 2019509988 A JP2019509988 A JP 2019509988A JP 2018540786 A JP2018540786 A JP 2018540786A JP 2018540786 A JP2018540786 A JP 2018540786A JP 2019509988 A JP2019509988 A JP 2019509988A
Authority
JP
Japan
Prior art keywords
tnf
antibody
human
antibodies
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018540786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509988A5 (https=
Inventor
ヘドリック，ジョセフ
シア，エリザベス
イム，ポール
ルー，ジョセリン
パクソン，ベサニー
リグビー，マーク
ジャン，ソンマオ
ゾカ，ラミネ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド, ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2019509988A publication Critical patent/JP2019509988A/ja
Publication of JP2019509988A5 publication Critical patent/JP2019509988A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A61M5/003—Kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31566—Means improving security or handling thereof
    • A61M5/31573—Accuracy improving means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31591—Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2018540786A 2016-02-05 2017-02-02 １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用 Pending JP2019509988A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291673P 2016-02-05 2016-02-05
US62/291,673 2016-02-05
PCT/US2017/016175 WO2017136524A2 (en) 2016-02-05 2017-02-02 Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Publications (2)

Publication Number Publication Date
JP2019509988A true JP2019509988A (ja) 2019-04-11
JP2019509988A5 JP2019509988A5 (https=) 2020-02-27

Family

ID=59500155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540786A Pending JP2019509988A (ja) 2016-02-05 2017-02-02 １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用

Country Status (11)

Country Link
US (3) US10465003B2 (https=)
EP (1) EP3411504A4 (https=)
JP (1) JP2019509988A (https=)
KR (1) KR20180105711A (https=)
CN (1) CN109072303A (https=)
AU (1) AU2017215317A1 (https=)
BR (1) BR112018015754A2 (https=)
CA (1) CA3012465A1 (https=)
MA (1) MA43982A (https=)
MX (1) MX2018009498A (https=)
WO (1) WO2017136524A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021075535A1 (ja) * 2019-10-18 2021-04-22 国立大学法人滋賀医科大学 異常幹細胞を標的とする糖尿病治療
WO2021075536A1 (ja) * 2019-10-18 2021-04-22 国立大学法人滋賀医科大学 幹細胞遊走剤を使用した糖尿病治療
WO2022181797A1 (ja) * 2021-02-26 2022-09-01 国立大学法人滋賀医科大学 糖尿病および合併症の新規治療、診断および検出のための方法および剤
JP2023524668A (ja) * 2020-04-27 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎を治療するための材料及び方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
EP3781941B1 (en) 2018-04-20 2026-01-14 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-tnf antibody compositions
JP7689074B2 (ja) * 2019-01-15 2025-06-05 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
WO2020152544A1 (en) * 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EA202192505A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
KR20210141998A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 제조 방법
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
WO2021028752A1 (en) * 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4108258A4 (en) * 2020-02-20 2024-03-06 Bio-Thera Solutions, Ltd. PREPARATION OF ANTI-TNF-ALPHA ANTIBODY, METHOD OF PREPARATION AND USE THEREOF
IL298389A (en) * 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung
WO2022171685A1 (en) * 2021-02-10 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Tnf-alpha blocking agent for preventing, suppressing and/or delaying the onset of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
US12534524B2 (en) 2021-07-09 2026-01-27 Janssen Biotech, Inc. Manufacturing methods for producing anti-TNF antibody compositions
KR20250031013A (ko) * 2023-08-23 2025-03-06 (주)셀트리온 TNFα 관련 질환을 치료하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523209A (ja) * 2000-08-07 2004-08-05 セントカー・インコーポレーテツド 抗−ｔｎｆ抗体、組成物、方法および使用
JP2008502596A (ja) * 2004-04-09 2008-01-31 アボツト・バイオテクノロジー・リミテツド ＴＮＦα関連障害を治療するための複数可変投薬計画
JP2009508476A (ja) * 2005-08-31 2009-03-05 セントカー・インコーポレーテツド 高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309640B1 (en) 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4822776A (en) 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS58501544A (ja) 1981-09-08 1983-09-16 ザ　ロツクフエラ−　ユニヴア−シテイ エンドトキシン誘発メディエ−タ−（ショック検定）によるリポプロティンリパ−ゼの抑圧
US6419927B1 (en) 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JPS61100158A (ja) 1984-10-22 1986-05-19 Fukuarare Honpo:Kk 納豆付米菓の製造方法およびその製品
EP0613006A1 (en) 1985-08-16 1994-08-31 The Rockefeller University Antibodies to cachectin and immunoassays
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8805792D0 (en) 1988-03-11 1988-04-13 Celltech Ltd Medicaments
DE3823804A1 (de) 1988-07-14 1990-01-18 Basf Ag Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
NZ229922A (en) 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5360716A (en) 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
JPH02227095A (ja) 1988-10-24 1990-09-10 Otsuka Pharmaceut Co Ltd モノクローナル抗体
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5342613A (en) 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
PT92900A (pt) 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
US4936843A (en) 1989-02-16 1990-06-26 Ace Orthopedic Manufacturing Kirschner wire clamp and tensioner
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP1857553A1 (en) 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
ES2196002T3 (es) 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0525570A3 (en) 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
NO178839C (no) 1991-11-25 1996-06-12 Ottestad Nils T Strömningsregulator for opprettholdelse av en stabil strömningsmengde av et fluidum
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2121907T3 (es) 1992-08-28 1998-12-16 Bayer Ag Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
CA2146647C (en) 1992-10-08 2009-05-05 Marc Feldmann Treatment of autoimmune and inflammatory disorders
EP0671936A1 (en) 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
SE9302490D0 (sv) 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9403909D0 (en) 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
FR2728793A1 (fr) 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
JPH11127855A (ja) 1997-10-27 1999-05-18 Japan Energy Corp 組換え型抗ヒトＴＮＦ−αヒトモノクローナル抗体
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
AU2003225976A1 (en) 2002-03-26 2003-10-13 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
US8188223B2 (en) * 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
AU2014224174B2 (en) * 2013-03-06 2018-08-30 Hadasit Medical Research Services And Development Ltd. Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523209A (ja) * 2000-08-07 2004-08-05 セントカー・インコーポレーテツド 抗−ｔｎｆ抗体、組成物、方法および使用
JP2008502596A (ja) * 2004-04-09 2008-01-31 アボツト・バイオテクノロジー・リミテツド ＴＮＦα関連障害を治療するための複数可変投薬計画
JP2009508476A (ja) * 2005-08-31 2009-03-05 セントカー・インコーポレーテツド 高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DIABETES CARE, 2009, VOL.32, NO.7, PP.1244-1249, JPN6021005246, ISSN: 0004833784 *
DIABETES CARE, 2013, VOL.36, PP.E90-E91, JPN6021005247, ISSN: 0004833785 *
DIABETES CARE, 2015, VOL.38, PP.1964-1974, JPN6021005249, ISSN: 0004675981 *
DIABETES, 2015, VOL.64, PP.2880-2891, JPN6021005248, ISSN: 0004675980 *
JOURNAL OF EXPERIMENTALMEDICINE, 1994, VOL.180, PP.995-1004, JPN6021052675, ISSN: 0004833787 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, 2005, VOL.102, NO.44, PP.15995-16000, JPN6021005250, ISSN: 0004447068 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021075535A1 (ja) * 2019-10-18 2021-04-22 国立大学法人滋賀医科大学 異常幹細胞を標的とする糖尿病治療
WO2021075536A1 (ja) * 2019-10-18 2021-04-22 国立大学法人滋賀医科大学 幹細胞遊走剤を使用した糖尿病治療
JPWO2021075536A1 (https=) * 2019-10-18 2021-04-22
JPWO2021075535A1 (https=) * 2019-10-18 2021-04-22
JP2023139101A (ja) * 2019-10-18 2023-10-03 株式会社バイオジップコード 幹細胞遊走剤を使用した糖尿病治療
JP7784120B2 (ja) 2019-10-18 2025-12-11 株式会社バイオジップコード 幹細胞遊走剤を使用した糖尿病治療
JP2023524668A (ja) * 2020-04-27 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎を治療するための材料及び方法
WO2022181797A1 (ja) * 2021-02-26 2022-09-01 国立大学法人滋賀医科大学 糖尿病および合併症の新規治療、診断および検出のための方法および剤
JPWO2022181797A1 (https=) * 2021-02-26 2022-09-01

Also Published As

Publication number Publication date
US20190375836A1 (en) 2019-12-12
EP3411504A2 (en) 2018-12-12
US20190092849A1 (en) 2019-03-28
US20170247444A1 (en) 2017-08-31
WO2017136524A2 (en) 2017-08-10
CN109072303A (zh) 2018-12-21
MX2018009498A (es) 2019-05-06
AU2017215317A1 (en) 2018-08-09
MA43982A (fr) 2018-12-12
CA3012465A1 (en) 2017-08-10
BR112018015754A2 (pt) 2019-01-29
KR20180105711A (ko) 2018-09-28
US10465003B2 (en) 2019-11-05
EP3411504A4 (en) 2019-09-11
US11124565B2 (en) 2021-09-21

Similar Documents

Publication Publication Date Title
US11124565B2 (en) Method for treating pre-type 1 diabetes in a human subject
US12291566B2 (en) Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
KR20190113858A (ko) 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
JP2025098055A (ja) 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
CA3142665A1 (en) Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
JP7689074B2 (ja) 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
WO2021028752A1 (en) Anti-tfn antibodies for treating type i diabetes
JP2025084901A (ja) 乾癬性関節炎の治療方法で使用するための抗ｔｎｆ抗体組成物
JP2023553702A (ja) 活動性強直性脊椎炎を処置するための抗ｔｎｆ抗体、組成物及び方法
KR20230005284A (ko) 소아 특발성 관절염을 치료하기 위한 재료 및 방법
EA048227B1 (ru) Композиции антител к фно для применения в способах лечения псориатического артрита
EA049997B1 (ru) Антитела к фно, композиции и способы лечения активного анкилозирующего спондилита

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220726